2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium - February 16-18, 2023 / San Francisco, CA and Virtual
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
READY: REAl-World Data from an Italian Compassionate Use Program of Avelumab First-Line Maintenance Treatment for locallY Advanced or Metastatic Urothelial Carcinoma (la/mUC) (includes PLS)
Antonuzzo | Poster #469
Full Analysis from AVENANCE: A Real-World Study of Avelumab First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
Barthélémy | Poster #471
Baseline Characteristics from a Retrospective, Observational, US-Based, Multicenter, Real-World Study of Avelumab First-Line Maintenance in Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC) (PATRIOT-II) (includes PLS)
Grivas | Poster #465
Real-World Treatment Patterns and Sequencing in Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) in the US
Kearney | Poster #572
Assessment of Treatment Patterns and Real-World Outcomes Following Changes in the Treatment Paradigm for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC) in the US
Kirker | Poster #468
A UK Real-World Observational Study of Avelumab + Axitinib (A + Ax) in Advanced Renal Cell Carcinoma (aRCC): 24-Month Interim Results (includes PLS)
Nathan | Poster #631
Treatment Patterns, Indicators of Receiving Systemic Treatment, and Clinical Outcomes in Metastatic Urothelial Carcinoma: A Retrospective Analysis of Real-World Data in Germany
Niegisch | Poster #464
Avelumab First-Line (1L) Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-Up from the JAVELIN Bladder 100 Trial in Subgroups Defined by 1L Chemotherapy Regimen and Analysis of Overall Survival from Start of 1L Chemotherapy (includes PLS)
Sridhar | Poster #508
SPADE: Design of a Real-World Observational Study of Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma in the Asia-Pacific Region
Su | Poster #577
C-Reactive Protein (CRP) as a Predictive Marker for Outcomes with Avelumab + Axitinib (A + Ax) in Patients with Poor-Risk Advanced Renal Cell Carcinoma (aRCC): Exploratory Analysis from JAVELIN Renal 101 (includes PLS)
Tomita | Poster #670
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: